Desmin(結蛋白)鼠單克隆抗體

廣州健侖生物科技有限公司

Desmin是一種中間絲蛋白，廣泛分布于骨骼肌、心肌、平滑肌及肌上皮細胞，其在腫瘤中表達的特點是高分化高表達、低分化低表達。此抗體既可以和人橫紋?。ü趋兰『托募。┑慕Y蛋白反應，又可以和平滑肌的結蛋白反應，與其它的中間絲蛋白（如波形蛋白、角蛋白、膠質纖維酸性蛋白、神經絲等）無交叉反應，主要用于骨骼肌、心肌和平滑肌及其來源的腫瘤的研究。

本次研究發現，大腸埃希菌，腸桿菌屬，肺炎克雷伯菌的ESBLs的檢出率zui高，分別是55.6%，40.0%和25.0%，對這三種細菌抗菌活性zui高的是亞胺培南，哌拉西林—三唑巴坦和頭孢吡肟，對產ESBLs菌而言，不同的ESBLs對不同的三代頭孢菌素具有不同的活性，某些ESBLs能賦予細菌對所有B-內酰胺類抗生素高水平的耐藥，而僅輕微提高耐藥性，而頭孢噻肟和頭孢他啶則是識別不同ESBLs的*底物 。至今為止，亞胺培南仍是作為治ESBLs菌的*藥。
嗜麥芽窄食單胞菌也是重癥肺炎較常見的多重耐藥致病菌，本次監測，除對左氧氟沙星（33.3%）外，對其他抗生素均耐藥嚴重，因其外膜通透性低，且可誘導B-內酰胺類L2、L1存在，所以對B-內酰胺類抗生素，氨基糖甙類，碳青霉烯類均高度耐藥，故該菌的感染已成為臨床治療的難題，目前研究發現，復方磺胺甲惡唑和替卡西林-棒酸是治療嗜麥芽窄食單胞菌感染zui為有效的藥物。

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

歡迎咨詢

歡迎咨詢

Desmin(結蛋白)鼠單克隆抗體

【產品介紹】

細胞定位：細胞漿

克隆號：D33

同型：IgG1/K

適用組織：石蠟/冰凍

陽性對照：闌尾

抗原修復：熱修復（EDTA）

抗體孵育時間：30-60min

Desmin(結蛋白)鼠單克隆抗體

想了解更多的產品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】     歐

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-103室

Desmin is a kind of intermediate silk protein, widely distributed in skeletal muscle, myocardium, smooth muscle and myoepithelial cells. Its expression in tumor is highly differentiated, poorly differentiated and poorly expressed. This antibody not only reacts with desmin in human striated muscle (skeletal muscle and myocardium) but also with desmokinin in smooth muscle, and interacts with other intermediate silk proteins such as vimentin, keratin, glial fibrillary acidic protein, ) No cross-reaction, mainly for skeletal muscle, myocardium and smooth muscle and the tumors of their origin.

The study found that the highest detection rate of Escherichia coli, Enterobacter, Klebsiella pneumoniae ESBLs were 55.6%, 40.0% and 25.0%, the highest antibacterial activity of these three bacteria is imine Penelope, Piperacillin-Tazobactam and Cefepime, for ESBLs-producing bacteria, different ESBLs have different activities on different third-generation cephalosporins and some ESBLs confer bacterial tolerance to all B-lactams Class antibiotics have high levels of resistance but only slightly increased resistance, whereas cefotaxime and ceftazidime are the best substrates for identifying different ESBLs. To date, imipenem is still the drug of choice for the treatment of ESBLs.
Stenotrophomonas maltophilia is also more common in severe pneumonia multi-drug resistant pathogens, the monitoring, except for levofloxacin (33.3%), the other antibiotics are resistant, because of its low permeability of the outer membrane, And can induce B-lactam L2, L1 exists, so the B-lactam antibiotics, aminoglycosides, carbapenems are highly resistant, so the bacteria infection has become a clinical problem, the current The study found that the compound sulfamethoxazole and ticarcillin - clavulanic acid treatment of Stenotrophomonas maltophilia the most effective drug.